BriaCell Therapeutics Closes Public Offering, Raises $3.05 MillionUnited States Securities and Exchange Commission, Washington, D.C. – February 3, 2025, BriaCell Therapeutics Corp. recently concluded a successful public offering. The Canadian biotech

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BriaCell Therapeutics’s 8K filing here.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.